Sleep peptide comparison

DSIP, Epitalon, and Pinealon for Sleep: What the Human Research Actually Says

A pseudonymous reader walks through the human evidence behind the three peptides that get marketed as sleep aids on biohacker forums, and finds three very different evidence bases hiding under one shared sales pitch.

by JoyBoy 13 min read Last reviewed May 2026 Mixed (🟡 / 🟡 / 🔴) None FDA approved

Educational content only. Not medical advice. Always consult a qualified healthcare provider before making decisions about your health.

30-second summary

WHAT THESE ARE

Three short peptides marketed for sleep. DSIP (9 amino acids, discovered in Switzerland in 1977). Epitalon (4 amino acids, developed in Russia by Khavinson and colleagues). Pinealon (3 amino acids, also Russian-developed, marketed for “neuroprotection” and sleep).

EVIDENCE

🟡 Human Observational for DSIP and Epitalon. 🔴 No Human Trials for Pinealon.

FDA STATUS

None of the three is FDA approved for any indication. None has a pending US new-drug application that I can find. All three sit in gray-market territory in the US.

HUMAN DATA

DSIP: small human sleep-architecture studies from the 1980s and early 1990s, mixed results. Epitalon: small Russian observational papers in aging populations, methodological concerns. Pinealon: essentially zero published human trials of any quality.

MY BOTTOM LINE

Three peptides, three evidence tiers, one shared marketing pitch. The biohacker community treats them as interchangeable. The literature does not. If you came here for “which one works best for sleep,” the honest answer is that the human evidence is too thin in all three cases to rank them by efficacy.

Why I looked into this 3 peptides at a glance What the human research shows Safety signals FDA & legal status Source safety My honest take Questions to ask What to do next

Why I looked into this

If you have spent any time on sleep-focused biohacker forums in the last few years, you have seen DSIP, Epitalon, and Pinealon mentioned in the same paragraph. Usually as a trio. Usually with a pitch that goes something like “the natural sleep peptides your pineal gland is missing.” Usually with a link to a vendor I will not name.

I went looking for the human evidence behind that pitch. What I found was three different molecules with three different evidence bases, none of them strong, all of them being sold as if they were equivalent. The biohacker community treats the trio as one product line. The literature treats them as three separate questions, each with a different answer, and the most heavily marketed one (Pinealon) has the thinnest human evidence of all three.

I have not used any of the three personally. This article is opinion plus literature review, not a diary entry.

Key takeaway: Three peptides in the same forum thread does not mean three peptides with the same evidence. The grading splits them apart fast.

The three peptides at a glance

The simplest honest framing is by amino acid length and country of origin, because both correlate with how much (and what kind of) human data exists.

DSIP (Delta Sleep-Inducing Peptide) is a 9-amino-acid peptide isolated by Monnier and Schoenenberger in Switzerland in 1977 from the cerebral venous blood of rabbits in a delta-sleep state. It was named for its association with delta-wave sleep, not because anyone proved it caused delta-wave sleep in humans. Through the 1980s and into the early 1990s, several small clinical studies looked at DSIP for chronic insomnia and other sleep complaints. The findings were mixed. Some studies reported improvements in sleep onset and subjective sleep quality. Others found no effect. The methodology by modern standards is dated, the sample sizes are small, and the field largely moved on. There is no large, modern, well-controlled human trial of DSIP for sleep that I can find.

Epitalon (also spelled Epithalon, sequence Ala-Glu-Asp-Gly) is a 4-amino-acid peptide developed in St. Petersburg by Vladimir Khavinson and colleagues. It was derived from epithalamin, an extract of the pineal gland. Khavinson’s group has published a long series of small Russian-language clinical papers in elderly populations, with claims that range from melatonin-rhythm normalization and improved sleep quality to broader effects on aging biomarkers and even mortality. The methodological concerns are significant. Most of the studies are small, single-center, and from one research group. Independent replication outside that group is sparse. Western journals have largely not engaged with the data.

Pinealon (sequence Glu-Asp-Arg) is a 3-amino-acid peptide also developed in the Khavinson lineage. It is marketed for “neuroprotection” and sleep, often as a companion to Epitalon. The published human research, as best I can tell, is essentially zero. There are some Russian-language preclinical papers and a handful of references in review articles, but I cannot find a published human clinical trial of any methodological quality testing Pinealon for sleep, cognition, or anything else. The marketing is loud. The evidence is silent.

Key takeaway: DSIP has old, small, mixed human data. Epitalon has small Russian observational data with methodological concerns. Pinealon has essentially no human evidence. The forum-level pitch flattens that into “three sleep peptides.” It should not.

What the human research shows

Question 01

Do published human trials exist for each of the three?

The honest answer is “for some, sort of, and not really.”

DSIP: Yes, but the trials are decades old and small. Schneider-Helmert published a series of papers in the 1980s on DSIP for chronic insomnia, with mixed results on sleep onset latency and subjective quality. Sample sizes were typically under 30. Several other small studies in the same era reached conflicting conclusions. There is no large modern RCT.
Epitalon: Yes, but mostly from one research group in one country, mostly in elderly populations, and mostly published in venues that Western evidence reviewers do not weight heavily. The grading is generous to call this 🟡; it is real human data, just not the kind of data that would clear a regulator’s bar.
Pinealon: No. I could not find a published human clinical trial that tests Pinealon for any sleep endpoint at any methodological level. If one exists in a journal I missed, I would update this. As of writing, the human evidence base is empty.

Question 02

What do the better-quality human findings actually claim?

For DSIP, the most-cited positive findings come from Schneider-Helmert and colleagues in the 1980s, reporting improvements in subjective sleep quality and reductions in sleep onset latency in chronic insomniacs at small sample sizes. Counter-findings exist. A 1986 review by Schneider-Helmert himself acknowledged the mixed picture and called for larger trials that were never run.

For Epitalon, the Khavinson group’s published claims include normalization of melatonin secretion patterns, improvements in subjective sleep quality in elderly subjects, and longer-term effects on aging biomarkers in cohorts followed for years. The trial designs are mostly observational or quasi-experimental rather than placebo-controlled RCTs. Independent replication outside the originating lab is, again, sparse.

For Pinealon, there is nothing of comparable quality to summarize. The marketing references mechanism of action and animal data. Neither qualifies as evidence of human effect.

Question 03

What does the research NOT show?

It is worth saying plainly what these findings do not establish:

That any of the three reliably outperforms placebo on any modern sleep endpoint at any meaningful sample size.
That the trio works as a group. There is no published human evidence supporting combination use of DSIP plus Epitalon plus Pinealon for sleep or anything else.
That the gray-market product sold under these names is the same molecule as the one tested in the original research. Purity, sterility, and identity are open questions for material that bypasses the licensed pharmacy chain.
That any of the three is a substitute for the parts of sleep health that consistent timing, light exposure, behavioral approaches like CBT-I, and addressing sleep apnea actually fix.
That anyone has ranked the three head to head. There is no human study comparing DSIP versus Epitalon versus Pinealon for sleep. Anyone telling you which is “best” is making it up.

About the animal studies: all three peptides have generated more rodent and in vitro work than human research, especially Pinealon. Animal results fail to replicate in humans most of the time, and the peptides where animal data is most exciting are usually the ones where human data is thinnest. That pattern fits this trio almost perfectly. I am not citing the animal work as evidence of human effect, and you should be skeptical of anyone who does.

Safety signals in humans (what we know and what we do not)

The honest answer on safety is “we do not know enough to give you a clean answer.” That is itself a safety signal.

For DSIP, the older human studies generally reported it as well tolerated at the small sample sizes involved. That is not the same as a modern safety database. Long-term safety, drug interactions, effects in vulnerable populations, and rare adverse events are not characterized at the level a regulator would expect.

For Epitalon, the Khavinson group’s papers report a generally benign side effect picture in their elderly cohorts. Independent verification is thin. The same caveats about long-term safety apply.

For Pinealon, there is essentially no human safety data to summarize. “We have not seen problems” is not a meaningful statement when nobody has run the kind of trial that would find them.

Add to that the gray-market layer. The product sold online under any of these names is not the same product that appeared in the original published research. Sterility, purity, peptide identity, and contamination by endotoxin or solvents are all open questions for material that did not come through a licensed pharmacy. The human safety signal you actually face is not the one in the 1986 paper. It is the one introduced by the supply chain.

Key takeaway: Limited adverse signals in old, small studies are not the same as a modern safety database. The supply chain risk is its own category and does not show up in the literature at all.

FDA and legal status

DSIP

Not FDA approved for any indication. Not a recognized prescription drug in the US. Not on the 503A bulks list as a compoundable substance. Sold in the US only as research-use-only material.

Epitalon

Not FDA approved. Not on the 503A bulks list. Has been used clinically in Russia for decades but has no US regulatory pathway. Sold in the US only as research-use-only material.

Pinealon

Not FDA approved. Not on the 503A bulks list. No US clinical recognition. Sold in the US only as research-use-only material.

503A and the bulks list

The 503A compounding framework lets a state-licensed pharmacy compound a peptide for an individual patient with a valid prescription, but only if the substance is on the FDA’s approved bulks list (or has another lawful pathway). None of these three is on that list. A licensed 503A pharmacy compounding any of them is operating outside the recognized framework.

The 2025 to 2026 wave of FDA scrutiny on peptide compounding (the docket FDA-2025-N-6895 review and the PCAC meetings in July 2026) tightened the conversation around what 503A pharmacies can lawfully make. None of these three sleep peptides was even on the table for that review, because none of them had the regulatory standing to be considered. They are not “in the queue.” They are outside it.

Key takeaway: All three are in the same legal bucket in the US: not FDA approved, not on the 503A bulks list, sold only as research-use-only material. Advisory-committee inclusion is not FDA approval, and these three are not even at the advisory-committee stage.

I built a doctor visit-prep one-pager specifically for the sleep-peptide conversation. Evidence summary, side effect questions, and what to ask before considering anything in this category. Free PDF. No upsell.

Get the sleep-peptide visit-prep one-pager

How to evaluate a source: the safety framework

Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name sellers. I do not link to anyone. I am teaching you how to think about a source so you can have an informed conversation with a clinician.

Green flags

A clinician who is willing to say “the human evidence here is too thin to recommend” and walk away
Independent third-party testing of any compounded product, with the certificate of analysis available on request
A licensed pharmacy operating in its jurisdiction with a clear physical address and accreditation
Plain disclosure that none of these three peptides is FDA approved or on the 503A bulks list
Honest acknowledgement that the published human evidence is limited and dated

Red flags

“Research use only” labeling on a vial that is being marketed for human use
“Pineal gland support” or “natural sleep peptide” marketing that flattens three different molecules into one pitch
Claims of efficacy for Pinealon, citing animal data or mechanism instead of human trials
Urgency or scarcity language (“last batch”, “before the FDA cracks down”)
Refusal to provide independent third-party lab testing or a real certificate of analysis

The wrinkle for this comparison specifically

Sleep peptides are unusual in that the pitch leans heavily on a story about your pineal gland and “natural” peptides your body is “missing.” That framing dresses up a thin human evidence base in language that sounds biological. None of these three is a vitamin you are deficient in. None has the human evidence base that, say, modern sleep-medicine pharmacology has, never mind the behavioral approaches with the strongest data. Anyone selling you all three as a “set” is selling a product line, not a finding.

Cost reality

The marketing pitch usually frames these peptides as cheap compared to FDA-approved sleep medications. That is true on a per-vial basis. It is not true on a risk-adjusted basis once you account for the supply chain uncertainty, the absent safety database, and the fact that the molecule in the vial has not been through the testing the comparison drug has. The price gap is real. The product gap is also real.

Questions worth asking any source

Where is this synthesized? Where is it independently tested? What is the peptide identity and purity, by mass spectrometry, on a current certificate of analysis? Who is the prescribing clinician of record? What happens if I have a reaction? A real source has answers. A bad one has marketing copy about pineal glands.

Key takeaway: The pitch for sleep peptides leans on biological-sounding language to compensate for thin human evidence. The supply chain risk is the part that does not get marketed. Ask the questions before you commit.

My 503A Source-Safety Checklist is the single most useful tool on this site. Free PDF. No upsell. It is what I use myself before considering any compounded peptide.

Download the source-safety checklist

My honest take

This section is opinion, not evidence. I am not endorsing use of any of these peptides. Everything above this line is sourced from published human research and regulatory documents. Everything below is my personal perspective as one pseudonymous reader. It is not medical advice. Your situation is not my situation. Do not treat this as a recommendation to try anything.

I have not used any of these three. I read the literature, I read the forums, and I came away skeptical of all three pitches but not equally skeptical of all three molecules. DSIP at least has a plausible biological story and old human data that is mixed but not nonexistent. Epitalon has a real research lineage and real human cohorts, even if the methodology and the single-lab problem make the data hard to bank on. Pinealon, as best I can tell, is a marketing molecule. The published human evidence base is not “thin,” it is essentially absent.

“Three peptides marketed as one product line. Three evidence bases that look nothing alike when you actually open the journals.”

Two things I would push back on if I heard them at a cocktail party. First, “they are all natural sleep peptides your body is missing” is not a finding, it is a tagline. The body does not have a known DSIP or Epitalon deficiency syndrome. Second, “the Russian research counts the same as Western trials” misses the point. Plenty of Russian research is good. The specific Khavinson-lineage literature on Epitalon and Pinealon is mostly small, mostly single-lab, and largely unreplicated. That is not a slur, it is a description. Real evidence reviewers weight it accordingly.

“If I had a sleep problem worth solving, I would start with the things that have the strongest human evidence: timing, light, behavior, and a sleep specialist who can rule out apnea. Not three peptides with a forum thread for a citation.”

If a friend asked me “which of the three is most worth knowing about,” I would say DSIP, mostly because it has the longest history of being studied in humans at all, and Epitalon a distant second. I would not hand them Pinealon under any framing. None of that is a recommendation to try any of them. The legitimate version of “I am not sleeping well” is a sleep specialist, not a vial.

Questions to ask your doctor

If you are considering any of these three, here are the questions I would want answered before walking out of the appointment, in order.

Have we ruled out the high-yield causes of poor sleep first? Sleep apnea, circadian misalignment, restless legs, and medication side effects account for a lot of “I have tried everything” sleep complaints. None of the three peptides in this article is a substitute for a real sleep workup.
What is your read of the human evidence for DSIP, Epitalon, and Pinealon specifically? A clinician who has actually read the literature can answer this. One who repeats forum talking points cannot.
If we considered any of these, what is the clinical rationale and the stop condition? What outcome are we tracking, on what timeline, and at what point do we conclude it is not working and discontinue?
How would we monitor for adverse events given that the long-term safety database is essentially nonexistent? What labs, what symptom check-ins, what threshold for stopping?
Where would the compounded product come from, and can we see the certificate of analysis? If the answer is “research-use-only material from an online seller,” that is the answer. The follow-up question is whether that is acceptable to either of you.
Have we exhausted the interventions with stronger human evidence first? Cognitive behavioral therapy for insomnia, timed light exposure, and an honest medication review will outperform a Pinealon vial in almost every case where they have not already been tried.

I built a peptide-specific visit-prep packet to take into your appointment. Evidence summary, doctor questions, space for notes. Free PDF.

Get the visit-prep packet

What to do next

If you are curious

Read the individual monographs. Each one walks the human data in detail and is graded honestly. Pick the molecule that matches what the literature actually says, not the one with the loudest forum post.

Read the DSIP monograph →

If you are considering

Have the conversation with a sleep specialist or a clinician you can actually reach. Bring the visit-prep packet. Bring your stop condition before you start. Make sure the high-yield sleep causes have been ruled out first.

Get the visit-prep packet →

If you have decided

Use the source-safety checklist before committing to any provider or pharmacy. None of these three is on the 503A bulks list, which is its own signal worth taking seriously.

Download the source-safety checklist →

Sources

Monnier M, Schoenenberger GA. Characterization, sequence, synthesis and specificity of a delta (EEG) sleep inducing peptide. In: Sleep 1976: Memory, Environment, Epilepsy, Sleep Staging. Karger; 1977. Foundational DSIP discovery paper. Funding: academic.
Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983;9(4):197-206. Small human series. Funding: academic.
Schneider-Helmert D. DSIP in sleep disorders. Eur Neurol. 1986;25 Suppl 2:154-7. Author’s own review acknowledging mixed findings. Funding: academic.
Khavinson VK. Peptides and ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. Comprehensive Khavinson-lab review covering Epitalon and related peptides. Funding: institutional (St. Petersburg Institute of Bioregulation and Gerontology).
Korkushko OV, Khavinson VK, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366-9. Long-term Russian observational data on Epitalon-class peptides. Funding: institutional.
Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide regulation of cell differentiation. Stem Cell Rev Rep. 2020;16(1):118-125. Review touching on Pinealon mechanism, mostly preclinical. Funding: institutional.
US FDA. Compounded drug products that are essentially copies of approved drug products under section 503A of the Federal Food, Drug, and Cosmetic Act. Guidance and bulks list updates, 2023 to 2026.
US FDA. Docket FDA-2025-N-6895 and Pharmacy Compounding Advisory Committee meeting materials, July 2026.

Funding for the Epitalon and Pinealon literature is largely institutional and concentrated in one research lineage. That is worth saying plainly. Single-lab concentration does not invalidate the data, but it is part of how the data should be read. The DSIP literature is older and academically funded, but the sample sizes are too small to support strong claims.

Related monographs

DSIP

The original sleep peptide. Old, small, mixed human studies. 🟡 grade with caveats.

Epitalon

The Russian-developed pineal peptide. Real human cohorts, single-lab problem, methodological concerns. 🟡 with caveats.

Pinealon

The marketing molecule. Essentially zero human evidence. 🔴.

The Peptide File provides educational content based on published research. This article is not medical advice. The Peptide File does not sell, distribute, or facilitate the purchase of any peptide compound. Always work with a qualified healthcare provider.